Dalbavancin
Also known as: A-40926 derivative, ABT‑492, BI-397, Dalbavancin, Dalvance, Xydalba
Source Dalbavancin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Dalbavancin is a semi‑synthetic lipoglycopeptide administered intravenously for the treatment of acute bacterial skin and skin‑structure infections (ABSSSI), including those caused by MRSA.
Mechanism of Action
Binds to the D-Ala-D-Ala terminus of peptidoglycan precursors, inhibiting transglycosylation and cross‑linking of the bacterial cell wall, leading to cell death.
Routes of Administration
Goals & Uses
- OsteomyelitisAnti InfectiveModerate
- Enable outpatient parenteral antimicrobial therapy (OPAT)Care SettingModerate
- Native and prosthetic valve endocarditis (off-label)Anti InfectiveLow
- Treat acute bacterial skin and skin‑structure infections (ABSSSI)InfectionHigh
- Acute bacterial skin and skin structure infections (ABSSSI)Anti InfectiveHigh
- MRSA infectionsAnti InfectiveHigh
- Outpatient parenteral antibiotic therapy (OPAT)Anti InfectiveModerate
Contraindications
- Severe renal impairment (CrCl <30 mL/min) without dose adjustmentRenalModerate
- Hypersensitivity to dalbavancin or other glycopeptide antibioticsAllergyHigh
- Hypersensitivity to other glycopeptides (e.g., vancomycin)AllergyModerate
- Known hypersensitivity to dalbavancinAllergyHigh
Adverse Effects
- HepatotoxicityHepaticUncommonLiver injury or dysfunction
- Infusion‑related reactions (e.g., flushing, pruritus)VascularCommon
- AnaphylaxisImmunologicRareSevere life-threatening allergic reaction
- Elevated hepatic enzymesHepaticUncommon
- Hypersensitivity/anaphylaxisImmunologicalRare
- HeadacheNeurologicCommonPain in the head or upper neck
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- DiarrheaGastrointestinalCommonLoose or frequent stools
- Infusion-related reactions (Red Man Syndrome)Infusion ReactionUncommon
Drug Interactions
- Nephrotoxic agents (e.g., aminoglycosides, vancomycin)Moderate
- WarfarinLow
- VancomycinLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Hepatic impairment (moderate to severe)Organ ImpairmentRelative
- Pediatric patients <6 monthsPediatricRelative
- Pediatrics (<18 years)AgeAbsolute
- Severe hepatic impairmentOrgan ImpairmentRelative
- Renal impairment (CrCl <30 mL/min, not on dialysis)RenalRelative
Regulatory Status
- European UnionApprovedApproved: ABSSSIApproved by EMA; same dosing recommendations as US.
- United StatesApprovedApproved: acute bacterial skin and skin‑structure infectionsApproved under brand Dalvance; dosing options include single 1500 mg dose or two‑dose regimen.
- United KingdomApprovedApproved: ABSSSIAvailable via NHS as Dalvance.
FDA approved in 2014 (brand name Dalvance) for ABSSSI; approved in the EU and other jurisdictions for the same indication.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Dalbavancin?
Dalbavancin is a semi‑synthetic lipoglycopeptide administered intravenously for the treatment of acute bacterial skin and skin‑structure infections (ABSSSI), including those caused by MRSA.
What is Dalbavancin used for?
Dalbavancin is educationally associated with: Osteomyelitis, Enable outpatient parenteral antimicrobial therapy (OPAT), Native and prosthetic valve endocarditis (off-label), Treat acute bacterial skin and skin‑structure infections (ABSSSI), Acute bacterial skin and skin structure infections (ABSSSI), MRSA infections, Outpatient parenteral antibiotic therapy (OPAT). Educational only — not medical advice.
How is Dalbavancin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Dalbavancin?
Reported adverse effects include: Hepatotoxicity, Infusion‑related reactions (e.g., flushing, pruritus), Anaphylaxis, Elevated hepatic enzymes, Hypersensitivity/anaphylaxis, Headache, Nausea, Diarrhea, Infusion-related reactions (Red Man Syndrome). This list is not exhaustive — consult a qualified clinician.
Who should avoid Dalbavancin?
Recorded contraindications: Severe renal impairment (CrCl <30 mL/min) without dose adjustment, Hypersensitivity to dalbavancin or other glycopeptide antibiotics, Hypersensitivity to other glycopeptides (e.g., vancomycin), Known hypersensitivity to dalbavancin. Consult a qualified clinician before use.